262 related articles for article (PubMed ID: 25633785)
1. Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.
Miller KL; Lanthier M
Nat Rev Drug Discov; 2015 Feb; 14(2):83. PubMed ID: 25633785
[No Abstract] [Full Text] [Related]
2. Bracing for the biosimilar wave.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):152-154. PubMed ID: 28248938
[No Abstract] [Full Text] [Related]
3. Biosimilars: where we were and where we are.
Challand R; Gorham H; Constant J
J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
[TBL] [Abstract][Full Text] [Related]
4. Japanese regulation of biosimilar products: past experience and current challenges.
Arato T
Br J Clin Pharmacol; 2016 Jul; 82(1):30-40. PubMed ID: 26987746
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars: Key regulatory considerations and similarity assessment tools.
Kirchhoff CF; Wang XM; Conlon HD; Anderson S; Ryan AM; Bose A
Biotechnol Bioeng; 2017 Dec; 114(12):2696-2705. PubMed ID: 28842986
[TBL] [Abstract][Full Text] [Related]
6. Biologic Medicines Under the Microscope.
Cauchi R
State Legis; 2015; 41(7):12. PubMed ID: 26245000
[No Abstract] [Full Text] [Related]
7. [Regulatory aspects of biosimilars. Myths and facts].
Schneider CK; Weise M
Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
[TBL] [Abstract][Full Text] [Related]
8. Scientific and legal viability of follow-on protein drugs.
Dudzinski DM; Kesselheim AS
N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608
[No Abstract] [Full Text] [Related]
9. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
10. The GAIN Act legislation to combat antimicrobial resistance: Where do we stand?
Sfeir MM
Infect Control Hosp Epidemiol; 2018 Dec; 39(12):1499-1500. PubMed ID: 30334503
[No Abstract] [Full Text] [Related]
11. Assessing biosimilarity and interchangeability of biosimilar products.
Chow SC
Stat Med; 2013 Feb; 32(3):361-3. PubMed ID: 23307569
[No Abstract] [Full Text] [Related]
12. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
13. Implementation of the biosimilar pathway: economic and policy issues.
Grabowski H; Long G; Mortimer R
Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
[No Abstract] [Full Text] [Related]
14. Biosimilar and interchangable biologic medications.
Simonson W
Geriatr Nurs; 2016; 37(5):393-394. PubMed ID: 27637457
[No Abstract] [Full Text] [Related]
15. Considerations for Biologic Product Drug-Drug Interactions: A Regulatory Perspective.
Schrieber SJ; Pfuma-Fletcher E; Wang X; Wang YC; Sagoo S; Madabushi R; Huang SM; Zineh I
Clin Pharmacol Ther; 2019 Jun; 105(6):1332-1334. PubMed ID: 30844077
[No Abstract] [Full Text] [Related]
16. Biosimilars legislation awakens data exclusivity debate.
Hutson S
Nat Med; 2009 Nov; 15(11):1242. PubMed ID: 19893548
[No Abstract] [Full Text] [Related]
17. Using Data Exclusivity Grants to Incentivize Cumulative Innovation of Biologics' Manufacturing Processes.
Levi EL
Am Univ Law Rev; 2017; 66(3):911-70. PubMed ID: 28233970
[TBL] [Abstract][Full Text] [Related]
18. FDA sets hierarchy for biosimilars evidence.
Ratner M
Nat Biotechnol; 2014 Jul; 32(7):609. PubMed ID: 25004221
[No Abstract] [Full Text] [Related]
19. Orphanage at the FDA.
Chen E
J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
[No Abstract] [Full Text] [Related]
20. Regulatory watch: European regulatory experience with advanced therapy medicinal products.
Barkholt L; Voltz-Girolt C; Raine J; Salmonson T; Schüssler-Lenz M
Nat Rev Drug Discov; 2019 Jan; 18(1):8-9. PubMed ID: 30498203
[No Abstract] [Full Text] [Related]
[Next] [New Search]
